SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
Conditions
Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
Trial Timeline
Oct 1, 2021 → Oct 1, 2023
NCT ID
NCT04948788About SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04948788. Target conditions include Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04948788 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma